Celularity buys Alliqua’s wound care business for $29mm
Celularity Inc. paid $29mm in cash to acquire Alliqua BioMedical Inc.’s advanced biologic wound care business, including intellectual property, as well as any related development, marketing, supply, and license agreements.
- Medical Devices
- Gene Therapy, Cell Therapy
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.